170 related articles for article (PubMed ID: 27406023)
1. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
3. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
5. Structural and kinetic basis of steroid 17α,20-lyase activity in teleost fish cytochrome P450 17A1 and its absence in cytochrome P450 17A2.
Pallan PS; Nagy LD; Lei L; Gonzalez E; Kramlinger VM; Azumaya CM; Wawrzak Z; Waterman MR; Guengerich FP; Egli M
J Biol Chem; 2015 Feb; 290(6):3248-68. PubMed ID: 25533464
[TBL] [Abstract][Full Text] [Related]
6. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Andersen KL; Yadav R; Brixius-Anderko S; Scott EE; Olsen L; Jørgensen FS; Björkling F
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660148
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
10. Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Petrunak EM; DeVore NM; Porubsky PR; Scott EE
J Biol Chem; 2014 Nov; 289(47):32952-64. PubMed ID: 25301938
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Sharma K; Rojas Velazquez MN; Pandey AV; Jørgensen FS; Arendrup FS; Andersen KL; Björkling F
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204665
[TBL] [Abstract][Full Text] [Related]
13. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors.
Gumede NJ; Nxumalo W; Bisetty K; Escuder Gilabert L; Medina-Hernandez MJ; Sagrado S
Bioorg Chem; 2020 Jan; 94():103462. PubMed ID: 31818479
[TBL] [Abstract][Full Text] [Related]
14. Conformational selection dominates binding of steroids to human cytochrome P450 17A1.
Guengerich FP; Wilkey CJ; Glass SM; Reddish MJ
J Biol Chem; 2019 Jun; 294(26):10028-10041. PubMed ID: 31072872
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z
J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
[TBL] [Abstract][Full Text] [Related]
16. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the function of steroidogenic cytochrome P450 17A1.
Yadav R; Petrunak EM; Estrada DF; Scott EE
Mol Cell Endocrinol; 2017 Feb; 441():68-75. PubMed ID: 27566228
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Bordeau BM; Ciulla DA; Callahan BP
ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
[TBL] [Abstract][Full Text] [Related]
19. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
[TBL] [Abstract][Full Text] [Related]
20. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]